Limits...
Prospective monitoring reveals dynamic levels of T cell immunity to Mycobacterium tuberculosis in HIV infected individuals.

Mitchell JE, Chetty S, Govender P, Pillay M, Jaggernath M, Kasmar A, Ndung'u T, Klenerman P, Walker BD, Kasprowicz VO - PLoS ONE (2012)

Bottom Line: During follow-up 30 individuals were placed on ARVs and 4 progressed to active TB.Fluctuations in SFC did not correlate with CD4 count, viral load, treatment initiation, or progression to active TB.The RD1-Elispot appears to have limited value in this setting.

View Article: PubMed Central - PubMed

Affiliation: Ragon Institute of MGH, Harvard Medical School, Boston, Massachusetts, United States of America.

ABSTRACT
Monitoring of latent Mycobacterium tuberculosis infection may prevent disease. We tested an ESAT-6 and CFP-10-specific IFN-γ Elispot assay (RD1-Elispot) on 163 HIV-infected individuals living in a TB-endemic setting. An RD1-Elispot was performed every 3 months for a period of 3-21 months. 62% of RD1-Elispot negative individuals were positive by cultured Elispot. Fluctuations in T cell response were observed with rates of change ranging from -150 to +153 spot-forming cells (SFC)/200,000 PBMC in a 3-month period. To validate these responses we used an RD1-specific real time quantitative PCR assay for monokine-induced by IFN-γ (MIG) and IFN-γ inducible protein-10 (IP10) (MIG: r=0.6527, p=0.0114; IP-10: r=0.6967, p=0.0056; IP-10+MIG: r=0.7055, p=0.0048). During follow-up 30 individuals were placed on ARVs and 4 progressed to active TB. Fluctuations in SFC did not correlate with CD4 count, viral load, treatment initiation, or progression to active TB. The RD1-Elispot appears to have limited value in this setting.

Show MeSH

Related in: MedlinePlus

Prospective monitoring of RD1- specific IFN-gamma Elispot responses does not predict progression to active TB.Longitudinal Elispots are shown for SK 169, SK 236, SK325 and SK 351 all of whom progressed to active TB during the follow-up period and 2 of which (SK 325 and SK 351) were also subsequently placed on ARVS. TB Treatment was initiated shortly after diagnosis of active TB. Longitudinal CD4 and viral load data is also shown for all 4 individuals.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3369919&req=5

pone-0037920-g006: Prospective monitoring of RD1- specific IFN-gamma Elispot responses does not predict progression to active TB.Longitudinal Elispots are shown for SK 169, SK 236, SK325 and SK 351 all of whom progressed to active TB during the follow-up period and 2 of which (SK 325 and SK 351) were also subsequently placed on ARVS. TB Treatment was initiated shortly after diagnosis of active TB. Longitudinal CD4 and viral load data is also shown for all 4 individuals.

Mentions: Four individuals (SK 169, SK 236, SK 325 and SK 351) progressed to active TB during the period of follow-up (figure 6). All four did not show a striking change in RD1-specific responses upon progression to active TB. However, for SK351 the RD1-specific T cell response decreased slightly as the individual progressed to active TB (37 SFC to 19 SFC for ESAT-6, and 91 SFC to 4 SFC for CFP-10). TB treatment initiation was also not associated with striking changes in SFC. The exception to this was SK236 were TB treatment was associated with a marked increase in the CFP-10- specific response (14 SFC to 81 SFC).


Prospective monitoring reveals dynamic levels of T cell immunity to Mycobacterium tuberculosis in HIV infected individuals.

Mitchell JE, Chetty S, Govender P, Pillay M, Jaggernath M, Kasmar A, Ndung'u T, Klenerman P, Walker BD, Kasprowicz VO - PLoS ONE (2012)

Prospective monitoring of RD1- specific IFN-gamma Elispot responses does not predict progression to active TB.Longitudinal Elispots are shown for SK 169, SK 236, SK325 and SK 351 all of whom progressed to active TB during the follow-up period and 2 of which (SK 325 and SK 351) were also subsequently placed on ARVS. TB Treatment was initiated shortly after diagnosis of active TB. Longitudinal CD4 and viral load data is also shown for all 4 individuals.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3369919&req=5

pone-0037920-g006: Prospective monitoring of RD1- specific IFN-gamma Elispot responses does not predict progression to active TB.Longitudinal Elispots are shown for SK 169, SK 236, SK325 and SK 351 all of whom progressed to active TB during the follow-up period and 2 of which (SK 325 and SK 351) were also subsequently placed on ARVS. TB Treatment was initiated shortly after diagnosis of active TB. Longitudinal CD4 and viral load data is also shown for all 4 individuals.
Mentions: Four individuals (SK 169, SK 236, SK 325 and SK 351) progressed to active TB during the period of follow-up (figure 6). All four did not show a striking change in RD1-specific responses upon progression to active TB. However, for SK351 the RD1-specific T cell response decreased slightly as the individual progressed to active TB (37 SFC to 19 SFC for ESAT-6, and 91 SFC to 4 SFC for CFP-10). TB treatment initiation was also not associated with striking changes in SFC. The exception to this was SK236 were TB treatment was associated with a marked increase in the CFP-10- specific response (14 SFC to 81 SFC).

Bottom Line: During follow-up 30 individuals were placed on ARVs and 4 progressed to active TB.Fluctuations in SFC did not correlate with CD4 count, viral load, treatment initiation, or progression to active TB.The RD1-Elispot appears to have limited value in this setting.

View Article: PubMed Central - PubMed

Affiliation: Ragon Institute of MGH, Harvard Medical School, Boston, Massachusetts, United States of America.

ABSTRACT
Monitoring of latent Mycobacterium tuberculosis infection may prevent disease. We tested an ESAT-6 and CFP-10-specific IFN-γ Elispot assay (RD1-Elispot) on 163 HIV-infected individuals living in a TB-endemic setting. An RD1-Elispot was performed every 3 months for a period of 3-21 months. 62% of RD1-Elispot negative individuals were positive by cultured Elispot. Fluctuations in T cell response were observed with rates of change ranging from -150 to +153 spot-forming cells (SFC)/200,000 PBMC in a 3-month period. To validate these responses we used an RD1-specific real time quantitative PCR assay for monokine-induced by IFN-γ (MIG) and IFN-γ inducible protein-10 (IP10) (MIG: r=0.6527, p=0.0114; IP-10: r=0.6967, p=0.0056; IP-10+MIG: r=0.7055, p=0.0048). During follow-up 30 individuals were placed on ARVs and 4 progressed to active TB. Fluctuations in SFC did not correlate with CD4 count, viral load, treatment initiation, or progression to active TB. The RD1-Elispot appears to have limited value in this setting.

Show MeSH
Related in: MedlinePlus